AMWatch

Cytovac skrotter den danske børs og tager til Sverige

Det danske biotekselskab Cytovac stiler mod en svensk børsnotering. ”Den danske børs er simpelthen ikke attraktiv nok,” lyder det fra den adm. direktør. Selskabet har allerede inden børsnoteringen placeret en del af det kommende aktieudbud hos private investorer i Sverige og er lige nu i gang med en runde i Danmark.

Kim Arvid Nielsen, adm. direktør, Cytovac, vil gå på børsen i Sverige og ikke i Danmark.

Der er tilsyneladende grønnere på den anden side af Øresund for mange små- og mellemstore danske medicinal- og biotekvirksomheder.

I hvert fald har endnu et dansk life science-selskab nu besluttet sig for at blive børsnoteret i Sverige frem for i Danmark.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Why do Nordic funds have so few female portfolio managers?

Only 16 percent of fund managers in Sweden are women. The figure is 11 percent in Finland, while just 6 percent of fund managers in Denmark and Norway are female. AMWatch has talked to four Nordic women in finance in search of answers regarding this imbalance and hear about their career experiences. 

Fidelity plans to halve CO2 in investment portfolios by 2030

Fidelity International's target will initially be limited to portfolio companies' direct emissions and those that stem from energy the company buys, so-called Scope 1 and Scope 2 emissions. The manager intends to add Scope 3 emissions once it has access to better data.

Related articles

Trial banner

Latest news

Jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch